Gene · 1399
Papers2,191
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
81 to 100 of 2,191
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Characterization of two transcriptomic subtypes of marker-null large cell carcinoma of the lung suggests different origin and potential new therapeutic perspectives. | Virchows Arch | 2024 | 38168015 | PubTator, text mining | PubMed |
| Osimertinib Covalently Binds to CD34 and Eliminates Myeloid Leukemia Stem/Progenitor Cells. | Cancer Res | 2024 | 38095536 | PubTator, text mining | PubMed |
| ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma. | Oncogene | 2024 | 38066089 | PubTator, text mining | PubMed |
| Cancer-associated fibroblast exosome LINC00355 promotes epithelial-mesenchymal transition and chemoresistance in colorectal cancer through the miR-34b-5p/CRKL axis. | Cancer Gene Ther | 2024 | 38052858 | PubTator, text mining | PubMed |
| Propofol inhibits the proliferation, invasion, migration, and angiogenesis of oral squamous cell carcinoma through circ_0008898-mediated pathway. | Chem Biol Drug Des | 2024 | 37955304 | PubTator, text mining | PubMed |
| PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis. | Clin Cancer Res | 2024 | 37943631 | PubTator, text mining | PubMed |
| PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression. | Oncogene | 2024 | 37875657 | PubTator, text mining | PubMed |
| Screening and Activity Evaluation of Novel BCR-ABL/T315I Tyrosine Kinase Inhibitors. | Curr Med Chem | 2024 | 37211852 | PubTator, text mining | PubMed |
| Gender Differences in Soft Tissue and Bone Sarcoma: A Narrative Review. | Cancers (Basel) | 2023 | 38201628 | PubTator, text mining | PubMed |
| Clinically Relevant Genetic Considerations for Patients With Tetralogy of Fallot. | CJC Pediatr Congenit Heart Dis | 2023 | 38161665 | PubTator, text mining | PubMed |
| The Nexus of Inflammation-Induced Epithelial-Mesenchymal Transition and Lung Cancer Progression: A Roadmap to Pentacyclic Triterpenoid-Based Therapies. | Int J Mol Sci | 2023 | 38139154 | PubTator, text mining | PubMed |
| Reelin Signaling and Synaptic Plasticity in Schizophrenia. | Brain Sci | 2023 | 38137152 | PubTator, text mining | PubMed |
| Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies. | Signal Transduct Target Ther | 2023 | 38105263 | PubTator, text mining | PubMed |
| USP7 promotes non-small-cell lung cancer cell glycolysis and survival by stabilizing and activating c-Abl. | Clin Transl Med | 2023 | 38082439 | PubTator, text mining | PubMed |
| CXCR2 inhibition overcomes ponatinib intolerance by eradicating chronic myeloid leukemic stem cells through PI3K/Akt/mTOR and dipeptidylpeptidase Ⅳ (CD26). | Heliyon | 2023 | 38045173 | PubTator, text mining | PubMed |
| Predictive and prognostic biomarkers of bone metastasis in breast cancer: current status and future directions. | Cell Biosci | 2023 | 38041134 | PubTator, text mining | PubMed |
| The enrichment of Fanconi anemia/homologous recombination pathway aberrations in ATM/ATR-mutated NSCLC was accompanied by unique molecular features and poor prognosis. | J Transl Med | 2023 | 38041093 | PubTator, text mining | PubMed |
| CurveCurator: a recalibrated F-statistic to assess, classify, and explore significance of dose-response curves. | Nat Commun | 2023 | 38036588 | PubTator, text mining | PubMed |
| Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach. | Cell Commun Signal | 2023 | 38031192 | PubTator, text mining | PubMed |
| A Diagnosis of Maternal 22q Duplication and Mosaic Deletion following Prenatal Cell-Free DNA Screening. | Case Rep Genet | 2023 | 38025940 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1399/papers?page=5